Grants per year
Search results
-
Active
-
Prot #68284528MMY4002: Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
Singhal, S. (PD/PI)
Parexel, Janssen Research & Development, LLC
3/20/23 → 3/20/26
Project: Research project
-
Prot #TAK-573-1501: A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
Singhal, S. (PD/PI)
Pharmaceutical Research Associates, Inc., Takeda Development Center Americas, Inc.
12/8/22 → 12/8/25
Project: Research project
-
Prot #ALLO-605-201: A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-647 and ALLO-605, an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients with Relapsed/Refractory Multiple Myelom
Singhal, S. (PD/PI)
Covance Inc., Allogene Therapeutics, Inc.
2/1/22 → 2/1/25
Project: Research project
-
Prot #BB2121-EAP-001: Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming for Commercial Release
Singhal, S. (PD/PI)
DrugDev Inc., Celgene Corporation
12/8/20 → 1/30/26
Project: Research project
-
Prot #CC-92480-MM-002: A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory
Singhal, S. (PD/PI)
11/14/19 → 11/14/25
Project: Research project
-
Prot #CC-220-MM-001: A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 Monotherapy and in Combination with Other Treatments in Sub
Singhal, S. (PD/PI)
ICON Clinical Research, LLC, Celgene Corporation
10/10/19 → 10/10/25
Project: Research project